SAN DIEGO, Jan. 8, 2013 /PRNewswire/ -- Tandem Diabetes Care, Inc. ("Tandem") announced today a partnership with JDRF, the leading global organization focused on type 1 diabetes (T1D) research, to develop a first-of-its-kind, dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system using therapies in conjunction with insulin.

"An ambulatory device that can simultaneously deliver insulin along with other drug therapies that are used for optimal diabetes management is not currently commercially available," said Kim D. Blickenstaff , president and CEO of Tandem. "The combination of JDRF's expertise and advocacy along with Tandem's unique technology and passion for meeting unmet needs in the diabetes community offers the opportunity for an exciting step toward the ultimate artificial pancreas solution."

read the complete press release here:
PR Newswire (http://s.tt/1y7Hb)